Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003392 · ClinicalTrials.gov registry record · Phase 2
High-Dose Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Metastatic Breast Cancer
A Phase 2 study, sponsored by UNC Lineberger Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 61
- Enrollment target
NCT00003392 is a Phase 2 study that has completed, run by UNC Lineberger Comprehensive Cancer Center. The registered enrollment target is 61 participants.
The verdict
NCT00003392, a Phase 2 study, has completed, sponsored by UNC Lineberger Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 61 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of high-dose chemotherapy and peripheral stem cell transplantation in treating patients with recurrent or refractory metastatic breast cancer.
Interventions
- DRUG carboplatin
- DRUG cyclophosphamide
- DRUG paclitaxel
- DRUG melphalan
- BIOLOGICAL filgrastim
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 1997-09 |
| Est. Completion | 2003-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003392
The ClinicalTrials.gov registry entry for NCT00003392 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UNC Lineberger Comprehensive Cancer Center, which has 366 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which carboplatin is the first listed.
NCT00003392 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003392 about?
NCT00003392 is a clinical study titled "High-Dose Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Metastatic Breast Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase II trial...
What is the current status of trial NCT00003392?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 1997-09. Estimated completion is 2003-01.
What interventions are being tested in trial NCT00003392?
The interventions under investigation include: carboplatin (DRUG), cyclophosphamide (DRUG), paclitaxel (DRUG), melphalan (DRUG), filgrastim (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003392?
This trial is sponsored by UNC Lineberger Comprehensive Cancer Center, which has 366 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.